Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.

This study is currently recruiting participants.

Verified by Ophthalmic Consultants of Boston, November 2006

First Received: November 1, 2006 Last Updated: May 31, 2007 History of Changes

Sponsors and Collaborators:	Ophthalmic Consultants of Boston Genentech
Information provided by:	Ophthalmic Consultants of Boston
ClinicalTrials.gov Identifier:	NCT00395551

Purpose

The purpose of this study is to determine whether ranibizumab is effective in the treatment of choroidal neovascularization secondary to causes other then wet macular-degeneration.

Condition	Intervention	Phase
Choroidal Neovascularization	Drug: ranibizumab	Phase I

Genetics Home Reference related topics: X-linked juvenile retinoschisis

MedlinePlus related topics: Macular Degeneration

Drug Information available for: Ranibizumab

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind, Dose Comparison, Factorial Assignment, Safety/Efficacy Study
Official Title:	A Single Center Study of the Safety and Efficacy of Multiple Intravitreal Injections of Ranibizumab in Subjects With CNV Secondary to Causes Other Than AMD.

Further study details as provided by Ophthalmic Consultants of Boston:

Primary Outcome Measures:

The primary outcome measures for safety and tolerability

Secondary Outcome Measures:

The secondary outcome measures for efficacy

Estimated Enrollment:	30
Study Start Date:	December 2005

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

active choroidal neovascularization

Exclusion Criteria:

pregnancy,age-related macular degeneration, current eye infection or recent eye surgery, participating in other eye studies

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00395551

Contacts

Contact: Jeffrey S. Heier, M.D.	617-314-2611
Contact: Joy M. Bankert, R.N., B.S.N.	617-573-1021	jbankert@eyeboston.com

Locations

United States, Massachusetts
Ophthalmic Consultants of Boston	Recruiting
Boston, Massachusetts, United States, 02114

Sponsors and Collaborators

Ophthalmic Consultants of Boston

Genentech

Investigators

Principal Investigator:

Jeffrey S Heier, M.D.

Ophthalmic Consultants of Boston

More Information

No publications provided

Study ID Numbers:	FVF 3688 Non-AMD
Study First Received:	November 1, 2006
Last Updated:	May 31, 2007
ClinicalTrials.gov Identifier:	NCT00395551 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Ophthalmic Consultants of Boston:

choroidal neovascularization
Choroidal Neovascularization Not related to Age-Related Macular Degeneration

Study placed in the following topic categories:

Metaplasia
Eye Diseases
Choroid Diseases
Neoplasm Metastasis
Retinal Degeneration

Macular Degeneration
Neovascularization, Pathologic
Retinal Diseases
Choroidal Neovascularization

Additional relevant MeSH terms:

Uveal Diseases
Pathologic Processes
Metaplasia
Eye Diseases
Choroid Diseases

Retinal Degeneration
Macular Degeneration
Neovascularization, Pathologic
Retinal Diseases
Choroidal Neovascularization

ClinicalTrials.gov processed this record on May 07, 2009